Ken Griffin Aerovate Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 11,100 shares of AVTE stock, worth $21,201. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,100Holding current value
$21,201% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding AVTE
# of Institutions
94Shares Held
27.7MCall Options Held
185KPut Options Held
129K-
Ra Capital Management, L.P. Boston, MA9.19MShares$17.6 Million0.23% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$7.18 Million0.35% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$4.28 Million0.56% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$3.44 Million0.4% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$2.7 Million0.05% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $46.7M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...